|
Design characteristics of AdaPT in comparison to other trials |
||||||||
| VALUE [16] |
ASCOT-BPLA [17] |
DREAM [6,38] |
AdaPT |
|||||
|
|
||||||||
| Valsartan |
Amlodipine |
Amlodipine |
Atenolol |
Ramipril |
Placebo |
ACEi |
Diuretic |
|
| (n = 7649) |
(n = 7596) |
(n = 9639) |
(n = 9618) |
(n = 2.623) |
(n = 2.646) |
(n = 1.353) |
(n = 662) |
|
|
|
||||||||
| Study design |
RCT |
RCT |
RCT |
Observational study |
||||
| Endpoint |
New onset diabetes (secondary objective) |
New onset diabetes (tertiary objective) |
New onset diabetes or death (primary endpoint) |
New onset diabetes (primary evaluation criterion) |
||||
| Inclusion criteria |
||||||||
| Age (years) |
≥ 50 |
40–79 |
≥ 30 |
≥ 45 |
||||
| Hypertension |
160–210/<115 mmHg |
≥ 160/100 mmHg |
n.a. |
≥ 140/90 mmHg |
||||
| Fasting plasma glucose |
normal |
Normal |
110–125 mg/dl [6.1–7.0 mmol/l] |
110–125 mg/dl [6.1–7.0 mmol/l] |
||||
| Impaired glucose tolerance |
normal |
Normal |
140–199 mg/dl [7.8–11.0 mmol/l] |
no inclusion criterion |
||||
| Exclusion criteria |
||||||||
| Diabetes |
exclusion (for diabetes endpoint) |
exclusion (for diabetes endpoint) |
exclusion |
exclusion |
||||
| Cardiovascular disease |
possible |
Possible |
exclusion |
possible |
||||
| Follow-up (years) |
4.2 (mean) |
5.5 (median) |
3.0 (median) |
4 (planned) |
||||
| HR new-onset diabetes |
0.77 [95%CI 0.69–0.86] |
0.70 [95%CI 0.63–0.78] |
0.91 [95%CI 0.80–1.03] |
n.a. |
||||
|
n.a. = not available | ||||||||
Zidek et al. Cardiovascular Diabetology 2008 7:22 doi:10.1186/1475-2840-7-22 |
||||||||